SENTI BIOSCIENCES HOLDINGS I
SNTI · NASDAQ
Updated at 2026-10-14 09:31:18
- Today's High
- $0.31
- Today’s Low
- $0.25
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $0.31
- Previous Close
- $0.31
- Volume
- 142.79K
- Market Cap
- $9.92M
- P/E Ratio
- --
- EPS
- $-1.76
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 2 CORPORATE DRIVE, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080
- Country
- US
- Listing Date
- 2021-05-26
- Fiscal Year End
- December
- Shares Outstanding
- 31.14M
- CIK
- 0001854270
- Website
- www.sentibio.com
Senti Biosciences Inc (SNTI) is a leading biotechnology firm specializing in synthetic biology, leveraging its proprietary GeneCircuit platform to create programmable cell and gene therapies. Focused on advancing personalized medicine, Senti targets critical challenges in oncology and genetic disorders, bolstered by a strong development pipeline and strategic collaborations. The company is poised for growth as it aims to revolutionize engineered cell therapy and address substantial unmet medical needs within the biopharmaceutical landscape, making it a compelling prospect for institutional investors.
Financial Metrics
Revenue
2026-06-30
$17K
2026-03-31
$16K
2025-12-31
$22K
2025-09-30
$0
Operating Expenses
2026-06-30
$13.83M
2026-03-31
$11.51M
2025-12-31
$12.71M
2025-09-30
$16.94M
Net Income
2026-06-30
-$12.75M
2026-03-31
-$4.22M
2025-12-31
-$14.46M
2025-09-30
-$18.12M
Net Profit Margin
2026-06-30
-75K%
2026-03-31
-26.38K%
2025-12-31
-65.75K%
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.41
2026-03-31
$-0.14
2025-12-31
$-0.53
2025-09-30
$-0.69
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$13.82M
2026-03-31
-$3.53M
2025-12-31
-$13.57M
2025-09-30
-$16.04M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $17K | $16K | $22K | $0 |
| Operating Expenses | $13.83M | $11.51M | $12.71M | $16.94M |
| Net Income | -$12.75M | -$4.22M | -$14.46M | -$18.12M |
| Net Profit Margin | -75K% | -26.38K% | -65.75K% | -- |
| Earnings Per Share | $-0.41 | $-0.14 | $-0.53 | $-0.69 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$13.82M | -$3.53M | -$13.57M | -$16.04M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.